Solid Tumor Immunotherapy
Solid Tumor Immunotherapy - Related Videos
01:27
Tumor Immunotherapy
0 Views •
2024
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
13:37
A Mouse Tumor Model of Surgical Stress to Explore the Mechanisms of Postoperative Immunosuppression and Evaluate Novel Perioperative Immunotherapies
0 Views •
Cited by 33 •
2014
A mouse tumor model of surgical stress is used to explore how postoperative immune suppression promotes metastatic disease and to evaluate immunostimulatory perioperative therapies.
08:40
Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
0 Views •
Cited by 20 •
2013
The most commonly used method for generating large numbers of autologous dendritic cells (DCs) for use in tumor immunotherapy is described. The method uses IL-4 and GM-CSF to differentiate DCs from monocytes. The immature DCs are stimulated to mature and then loaded with antigens before they are injected back into the patient.
08:06
Experimental Metastasis and CTL Adoptive Transfer Immunotherapy Mouse Model
0 Views •
Cited by 21 •
2010
An experimental lung metastasis and CTL immunotherapy mouse model for analysis of tumor cells-T cell interaction in vivo.
08:08
Quantitative Mass Spectrometric Profiling of Cancer-cell Proteomes Derived From Liquid and Solid Tumors
0 Views •
Cited by 7 •
2015
In-depth analyses of cancer cell proteomes facilitate identification of novel drug targets and diagnostic biomarkers. We describe an experimental workflow for quantitative analysis of (phospho-)proteomes in cancer cell subpopulations derived from liquid and solid tumors. This is achieved by combining cellular enrichment strategies with quantitative Super-SILAC-based mass spectrometry.
FAQs
The immunosuppressive tumor microenvironment can limit immune-cell activation, trafficking, and persistence, even when immune cells recognize malignant targets. Bioengineered strategies therefore focus on helping therapeutic cells or agents function within the tumor and surrounding tissues. Improving these local conditions matters because effective treatment requires immune activity at the disease site, rather than immune recognition occurring elsewhere.
Checkpoint blockade works by blocking inhibitory signals that restrain antitumor immune responses, whereas engineered immune cells are designed to deliver immune activity directly through specialized cellular functions. Using either strategy, or combining them with other interventions, can address distinct limitations within tumors. This distinction helps researchers match therapeutic design to immune suppression and delivery challenges.
Tumor heterogeneity means that malignant cells within and around a tumor may not respond identically to one immune-based intervention. This variation can contribute to treatment resistance and limit the durability of responses. Bioengineering addresses the challenge through targeted delivery systems, engineered immune cells, and combination therapies intended to improve precision and maintain activity across complex tumor environments.
Biomaterials can support the development of therapeutic delivery systems, while synthetic receptors can engineer immune cells with selected recognition or activation capabilities. These tools give researchers ways to control where therapeutic agents act and how immune cells respond. In solid tumor research, their value lies in improving immune-cell trafficking, activation, and persistence within difficult tissue environments.
A strategy may combine biomaterials, targeted delivery systems, synthetic receptors, engineered immune cells, therapeutic agents, and checkpoint-directed interventions. Each element can address a different limitation, such as reaching the tumor, sustaining immune-cell activity, or reducing inhibitory signaling. Combining compatible components allows researchers to investigate whether coordinated interventions can overcome barriers that one approach alone may not resolve.
Bioengineers seek treatments that produce more precise and durable antitumor effects while improving immune-cell trafficking, activation, and persistence. These outcomes are especially relevant in solid tumors, where surrounding tissues and local immune suppression can restrict therapeutic function. The broader goal is to develop engineered interventions that better manage tumor heterogeneity and reduce the likelihood of treatment resistance.